Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer

International Journal of Cancer - United States
doi 10.1002/ijc.30533
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Clinical Implications of High MET Gene Dosage in Non-Small Cell Lung Cancer Patients Without Previous Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2015English

Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2015English

Usefulness of Bronchoscopic Rebiopsy of Non-Small Cell Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of Cancer
Oncology
2018English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy